Vancouver, BC — August 15, 2025 — Leads & Copy — Lobe Sciences Ltd. has closed a non-brokered private placement of up to 8,535,625 common shares at $0.04 per share, raising up to $341,425 CAD. The securities issued are subject to a four-month and one-day hold period. The offering was announced on July 29th. The biopharmaceutical company focuses on developing therapeutics for rare and underserved diseases.
Lobe Sciences is developing advanced treatments for rare and neurologically underserved conditions. Through its subsidiaries, Altemia, Inc., and Cynaptec Pharmaceuticals, Inc., Lobe is advancing a lipid-based delivery platform for Sickle Cell Disease and a proprietary oral analog of psilocin-Conjugated Psilocin™-targeted for Chronic Cluster Headache and related disorders.
Dr. Fred D. Sancilio, CEO
Info@Lobesciences.com
Phone: +1 (949) 505-5623
Source: Lobe Sciences Ltd.
